Chronic Kidney Dysfunction (Videos Available)

Wednesday July 04, 2018 from 09:45 to 10:45

Room: N-102

516.3 Inflammation in fibrotic areas (i-IF/TA) identifies a T cell-mediated rejection component of IF/TA with poor kidney allograft outcome

Yassine Bouatou, France

Dr
PARCC
INSERM

Abstract

Inflammation in Fibrotic Areas (i-IF/TA) Identifies a T cell-mediated Rejection Component of IF/TA with Poor Kidney Allograft Outcome

Denis Viglietti1, Olivier Aubert1, Jean-Paul Duong Van Huyen1, Alexandre Loupy1, Carmen Lefaucheur1.

1Paris Translational Research Center for Organ Transplantation, Paris, France

Addressing the etiological heterogeneity of interstitial fibrosis in kidney allografts represents an important challenge to improve long-term transplant outcomes. We investigated the determinants, clinical and histological phenotype, and outcome of i-IF/TA in a prospective cohort of kidney recipients.
We prospectively enrolled 1539 kidney recipients transplanted between 2004 and 2010, with systematic assessment of i-IF/TA using the i-IF/TA Banff score and of tubulitis in atrophic tubules (t-IF/TA), on allograft biopsies performed at 1 year post-transplantation. We considered donor, recipient and transplant baseline characteristics, immunosuppression, infectious diseases (CMV, pyelonephritis, BK virus), presence of donor-specific anti-HLA antibodies (DSAs) and all the biopsy-proven diagnoses (T cell-mediated rejection [TCMR], antibody-mediated rejection [ABMR], recurrence, BK virus-associated nephropathy [BKVAN], calcineurin inhibithor [CNI] toxicity, acute tubular necrosis) recorded within the first year after transplantation.
We identified 946 (61%) patients with IF/TA at one year post-transplant, among whom 394 (42%) patients showed i-IFTA, which was associated with t-IF/TA in 309 (78%) patients. Patients with i-IF/TA at 1 year post-transplant had significantly decreased allograft survival at 8 years compared with patients with non-inflammatory IF/TA (81% vs 87%, P=0.002). Independent risk factors for i-IF/TA included: TCMR (OR=2.7, p<0.001), BKVAN (OR=3.3, p=0.007) and HLA B (OR=1.3, p=0.012) and DR (OR=1.2, p=0.044) mismatching, while steroid therapy (OR=0.6, p=0.039), CNI therapy (OR=0.5, p=0.011) and inosine-5'-monophosphate dehydrogenase inhibitor therapy (OR=0.5, p=0.011) had protective effects on i-IF/TA occurrence. Unsupervised hierarchical clustering based on the whole spectrum of Banff elementary lesions assessed at 1 year post-transplant showed that i-IF/TA aggregated in the TCMR cluster (i, t, ti, t-IF/TA and i-IF/TA) and not in the ABMR (g, ptc, C4d, cg) and chronicity clusters (cv, ci, ct, ah). We observed a positive gradient between increasing level of i-IF/TA and t-IF/TA Banff scores and the risk of allograft loss (p<0.001).
i-IFTA may reflect a TCMR subcomponent of IF/TA related to under-immunosuppression and is associated with poor kidney transplant outcome compared to non-inflammatory IF/TA.



© 2024 TTS2018